In patients with depression, does initial treatment with fluoxetine improve clinical, quality of life, and economic outcomes better than desipramine or imipramine? D e s i g n Randomized (allocation concealed*), unblinded,* controlled trial with 24-month follow-up.
I n t e r v e n t i o n
Patients were allocated to {fluoxetine (n = 173), desipramine (n = 181), or imipramine (n = 182)} †.
M a i n o u t c o m e m e a s u r e s
Continuing use of initial medication; remission of depression; change in Hamilton Depression Rating Scale (HDRS) score, Hopkins Symptom Checklist (HSCL) depression subscale score, and SF-36 Mental Component Summary (MCS) score; and cost.
M a i n r e s u l t s
Patients who were allocated to fluoxetine were more likely to continue their original medication than were patients who received desipramine (P < 0.001) or imipramine (P < 0.001) (Table) . The likelihood of continuing any antidepressant drug decreased over time and was not affected by initial allocation (P = 0.95) (Table) . Groups did not differ in the proportion of patients with remission from depression or change in HDRS, HSCL, or SF-36 MCS scores. Drug costs were U.S. $250 more over 2 years in the fluoxetine group, but total cost of care did not differ between groups.
C o n c l u s i o n s
Patients who began antidepressant treatment with fluoxetine were more likely to continue taking it but not more likely to continue taking any antidepressant medication. Clinical and quality-of-life outcomes improved within 6 months of treatment and did not differ among the fluoxetine, desipramine, and imipramine groups. 
C o m m e n t a r y
This "real-life" study by Simon and colleagues gives us insight into how antidepressants are used in practice and the associated costs. Randomized controlled trials with economic modeling tell us a limited amount about the real world. We know that newer drugs cost more, but we do not know how their putative benefits translate into outcome or cost-effectiveness. In this study, the lower rate of switching because of adverse effects suggests that fluoxetine was better tolerated than tricyclics; outcome and willingness to continue taking antidepressants, however, was not affected. The human cost of this difference is difficult to know. Starting treatment with fluoxetine led to greater drug costs than with tricyclics, but switching between antidepressants reduced this difference. The increase in the acquisition costs of fluoxetine may have been balanced by lower medical costs, although the study had limited power to estimate these costs precisely. Therefore, the study could not detect a difference in total medical costs of about the same amount as the difference in drug prescription costs. Although we can be fairly confident that first-line fluoxetine led to a larger drug bill, we are less certain about how overall costs compared between groups. Even if the costs balance, interpretation depends on which budget you control and on your health care system. The situation is further complicated because we cannot assume that results with fluoxetine will be the same with other selective serotoninreuptake inhibitors and new antidepressants.
Was it appropriate to give any antidepressant to many of these patients with mainly mild depression? Below a certain threshold of severity, antidepressants are less likely to be beneficial (1); therefore, these patients could have had up to 2 years of unnecessary drug treatment. Targeting more severely ill patients is at least as important as choosing which antidepressant to use. 
